Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
VNz4DKBnbcRTjEZn